SLC5A2 and kidney disorder: Post-hoc subgroup analysis (based on metformin use) showed a higher risk of CV death, mortality, and nephropathy in the placebo arm of the metformin non-users than metformin users suggesting that metformin use might attenuate the effect of sodium-glucose transporter (SGLT-2) inhibitors on these outcomes [53].